The HS1BP3 Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HT29 human colorectal adenocarcinoma line. This product provides a loss-of-function model for the HS1BP3 gene, which encodes a scaffold protein involved in coupling the actin cytoskeleton to clathrin-coated vesicle formation. By disrupting HS1BP3 expression, the cells enable investigation of clathrin-mediated endocytosis and actin-dependent processes in a colorectal cancer context. The polyclonal nature of the knockout population ensures representation of multiple gene-edited alleles, facilitating robust functional studies without monoclonal selection artifacts.
HT29 cells are human colorectal adenocarcinoma epithelial cells established from a 44-year-old Caucasian female, serving as a well-characterized model for intestinal epithelial biology. They are extensively employed in studies of differentiation, transport mechanisms, and colorectal cancer pathogenesis. The adherent HT29 line retains key characteristics of intestinal epithelium, including the ability to polarize and form tight junctions, making it suitable for examining endocytic trafficking and migration in a cancer-relevant setting.
HS1BP3 functions as a critical scaffold protein that bridges the actin cytoskeleton to clathrin-coated pits, thereby coordinating vesicle internalization with local actin polymerization dynamics. It interacts with clathrin heavy chain, actin, phosphatidylinositol 4,5-bisphosphate (PIP2), HCLS1, and HSPA8 to facilitate endocytic site assembly. HS1BP3 is regulated upstream by Src family kinases and integrin signaling, and its activity converges on effectors such as the Arp2/3 complex, WASp, and cortactin to modulate branched actin network formation. Disruption of HS1BP3 interrupts clathrin-mediated endocytosis and actin reorganization, potentially impairing cell migration and focal adhesion turnover.
In HT29 colorectal adenocarcinoma cells, loss of HS1BP3 is expected to perturb clathrin-mediated endocytic trafficking and actin-dependent processes, both of which are frequently dysregulated in cancer. The HT29 model, with its established use in intestinal epithelial research, provides a relevant background to interrogate how HS1BP3 deficiency influences cell proliferation, invasive capacity, and metastatic potential. Moreover, given the association of HS1BP3 variants with essential tremor, this knockout population may aid in exploring shared molecular pathways between neurological and oncological disorders.
This knockout cell population is suited for a wide range of experimental approaches, including transferrin uptake assays to measure clathrin-mediated endocytosis efficiency, wound healing and Matrigel invasion assays to assess migration and invasion, and immunofluorescence with phalloidin staining to visualize F-actin organization. Additional validation can be performed via western blotting and RT-qPCR to confirm HS1BP3 loss, along with immunofluorescence co-staining of clathrin and actin to examine endocytic site integrity. The cells also provide a platform for drug screening targeting metastasis inhibitors and for dissecting the crosstalk between endocytosis and actin dynamics in colorectal cancer. For further technical inquiries or to discuss custom applications, please contact Ascent Research.
